Second dose of fat cells may offer new hope for Crohn's fistulas

NCT ID NCT07629245

Recruiting now Disease control Sponsor: Assistance Publique Hopitaux De Marseille Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests the safety of giving a second injection of a patient's own frozen fat-derived cells (stromal vascular fraction) to treat anal fistulas that didn't heal in a previous trial. About 25 adults with Crohn's disease who still have active fistulas will receive the injection. The main goal is to check for infections, worsening incontinence, or other side effects over six months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cryopreserved autologous stromal vascular fraction (fat-derived cells)
What this could lead to: If successful, this could provide a safe, repeatable treatment option for people with Crohn's disease who have persistent anal fistulas that don't heal with standard care.
What could go wrong: This is an early-phase (1/2) safety study with only 25 participants, so it's too small to prove effectiveness. The treatment involves a second injection, and risks like infection or worsening incontinence are being closely monitored.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CROHN DISEASE (CD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Crohn disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CROHN DISEASE (CD)

Contacts and locations

Locations

APHM hopital NORD
RECRUITING

Marseille, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.